WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 597741
Description: U 27391 inhibits the action of human recombinant interleukin-1beta and glycosaminoglycan synthesis. U 27391 is a metalloproteinase inhibitor.
MedKoo Cat#: 597741
Name: U 27391
Chemical Formula: C23H36N4O5
Exact Mass: 448.2686
Molecular Weight: 448.56
Elemental Analysis: C, 61.59; H, 8.09; N, 12.49; O, 17.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: U 27391; U-27391; U27391;
IUPAC/Chemical Name: N1-((S)-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)-N4-hydroxy-2-isobutylsuccinamide
InChi Key: HLSQLCOADIMQBK-MNNMKWMVSA-N
InChi Code: InChI=1S/C23H36N4O5/c1-14(2)10-17(13-20(28)27-32)22(30)26-19(11-15(3)4)23(31)25-18(21(24)29)12-16-8-6-5-7-9-16/h5-9,14-15,17-19,32H,10-13H2,1-4H3,(H2,24,29)(H,25,31)(H,26,30)(H,27,28)/t17?,18-,19-/m0/s1
SMILES Code: O=C(N)[C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC(C(CC(NO)=O)CC(C)C)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 448.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Steinmeyer J, Daufeldt S. Pharmacological influence of antirheumatic drugs on proteoglycans from interleukin-1 treated articular cartilage. Biochem Pharmacol. 1997 Jun 1;53(11):1627-35. PubMed PMID: 9264315.
2: Steinmeyer J, Daufeldt S, Kalbhen DA. The proteoglycan metabolism, morphology and viability of articular cartilage treated with a synthetic matrix metalloproteinase inhibitor. Res Exp Med (Berl). 1997;197(2):63-79. PubMed PMID: 9380952.
3: Seed MP, Ismaiel S, Cheung CY, Thomson TA, Gardner CR, Atkins RM, Elson CJ. Inhibition of interleukin 1 beta induced rat and human cartilage degradation in vitro by the metalloproteinase inhibitor U27391. Ann Rheum Dis. 1993 Jan;52(1):37-43. PubMed PMID: 8427512; PubMed Central PMCID: PMC1004953.